In a clinical trial of 14 children with B-ALL, addition of PD-1 blockades to CD19 CAR T-cell therapy improved persistence of the CAR T-cells and 7/14 patients maintained partial or complete remission (CR) [74]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.